H.C. Wainwright lowered the firm’s price target on Cybin to $5 from $10 and keeps a Buy rating on the shares. The target drop reflects the company’s equity issuances tied to the acquisition of Small Pharma and capital raises, the analyst tells investors in a research note. The firm believes Cybin’s psychiatry pipeline remains among the leaders in the space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CYBN:
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Cybin reports Q2 net income (C$11.9M) vs (C$10M) last year
- Cybin, Inc. (CYBN) Q2 Earnings Cheat Sheet
- Cybin’s depressive disorder candidate meets Phase 2 efficacy endpoint
- Cybin reports CYB003 demonstrated reduction in symptoms of depression
